Eli Lilly and Company Stock News

Shares of Lilly are cratering, but investors may be surprised to learn what's influencing the volatility.

In today's article I will try to answer the question on whether the two premier diet drug companies stocks have finally stopped going down? I will look at two stocks (dietary drug is in parenthesis): Novo Nordisk NYSE:NVO (Wegovy) and Eli Lilly NYSE:LLY (Zepbound) Today I read this: WEIGHT-LOSS DRUG COVERAGE RISES AMONG LARGE US

Eli Lilly and Hong Kong-listed Laekna will collaborate to develop an experimental obesity drug that aims to help patients lose weight while preserving muscle, the biotech said on Wednesday.

The collaboration will accelerate the global development of LAE102, a novel Activin Receptor Type 2 A (ActRII A ) Antagonistic Monoclonal Antibody (mAb) for muscle-preserving weight loss in Obesity LOS ANGELES , Nov. 20, 2024 /PRNewswire/ -- Laekna, Inc. (2105.HK) ("Laekna"), a global biotech company focused on novel drug development for metabolic and cancer diseases, is pleased to announce a c...

LOS ANGELES--(BUSINESS WIRE)-- #ActRII--Laekna, Inc. (2105.HK) (“Laekna”), a global biotech company focused on novel drug development for metabolic and cancer diseases, is pleased to announce a clinical collaboration with Eli Lilly and Company (Lilly), a global leader in cardiometabolic health, including diabetes and obesity, to accelerate the development of LAE102, a novel ActRIIA mAb as a nov...

A short strangle on Eli Lilly will generate $1,125 in option premium and takes advantage of the current high level of implied volatility. The post Eli Lilly Option Trade Produces $1,125, If You Can Tolerate The Heavy Risk appeared first on Investor's Business Daily.

Is It Time to Sell Eli Lilly and Pfizer Stocks?

— Lilly to Develop Two Targets Identified and Validated Using Verge Genomics' AI-Enabled, All-in-Human CONVERGE® Platform